Skip to contentB
Bone Biologics Corp
B
BBLGBone Biologics Corp Q1 2021 · 10-Q
Revenue$1.07B$1.07B±0.0% vs Q1 2020 Net Income-$431.75K-$431.75KN/M vs Q1 2020 EPS Diluted-$0.06-$0.06N/M vs Q1 2020 Operating Income-$180,924N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bone Biologics Corp · CIK 1419554 · Engraved from SEC EDGAR
Margins · derivedOperating margin-0.0%+0.0 pt vs Q1 2020
Net margin-0.0%+0.0 pt vs Q1 2020
ended Mar 31, 2021 · filed May 21, 2021 · 51 d after period end